13,100 Shares in Prestige Consumer Healthcare Inc. $PBH Bought by State of Wyoming

State of Wyoming bought a new stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) in the second quarter, HoldingsChannel reports. The fund bought 13,100 shares of the company’s stock, valued at approximately $619,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in PBH. UMB Bank n.a. lifted its position in Prestige Consumer Healthcare by 110.1% during the 4th quarter. UMB Bank n.a. now owns 418 shares of the company’s stock worth $26,000 after buying an additional 219 shares in the last quarter. Bayforest Capital Ltd acquired a new position in shares of Prestige Consumer Healthcare during the 4th quarter worth about $29,000. Versant Capital Management Inc grew its holdings in shares of Prestige Consumer Healthcare by 47.9% in the 2nd quarter. Versant Capital Management Inc now owns 726 shares of the company’s stock valued at $34,000 after acquiring an additional 235 shares in the last quarter. Torren Management LLC bought a new position in shares of Prestige Consumer Healthcare in the 4th quarter valued at about $35,000. Finally, Caitong International Asset Management Co. Ltd increased its position in shares of Prestige Consumer Healthcare by 69.8% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 574 shares of the company’s stock valued at $35,000 after acquiring an additional 236 shares during the last quarter. 99.95% of the stock is currently owned by institutional investors and hedge funds.

Prestige Consumer Healthcare Stock Performance

Shares of PBH opened at $51.51 on Monday. The firm has a 50-day moving average of $49.46 and a 200-day moving average of $55.51. Prestige Consumer Healthcare Inc. has a one year low of $42.62 and a one year high of $71.07. The company has a market cap of $2.44 billion, a PE ratio of 14.43, a price-to-earnings-growth ratio of 1.61 and a beta of 0.34. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.23 and a quick ratio of 1.99.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.89 by $0.09. The company had revenue of $265.71 million for the quarter, compared to analyst estimates of $253.02 million. Prestige Consumer Healthcare had a net margin of 15.57% and a return on equity of 11.39%. Prestige Consumer Healthcare’s revenue for the quarter was up 6.5% compared to the same quarter last year. During the same period in the previous year, the business earned $0.90 EPS. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. As a group, equities analysts forecast that Prestige Consumer Healthcare Inc. will post 4.56 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms recently issued reports on PBH. Canaccord Genuity Group dropped their target price on Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating on the stock in a report on Friday, May 15th. Oppenheimer downgraded Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 14th. Zacks Research raised Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a research report on Monday, August 10th. Finally, Weiss Ratings cut Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, June 25th. Two analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Prestige Consumer Healthcare currently has an average rating of “Hold” and an average target price of $70.75.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).